Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

The company is eyeing a pivotal trial for its dual-polymer hydrogel stomach implant following promising first-in-human trial ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

In Washington state, four agricultural workers tested presumptively positive for avian influenza after contact with infected ...

The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...